Khan Zakir, Khan Abdul Arif, Yadav Hariom, Prasad Godavarthi B K S, Bisen Prakash Singh
School of Studies in Biotechnology, Jiwaji University, Gwalior, 474001 MP India.
Department of Biomedical Sciences, Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA 90048 USA.
Cell Mol Biol Lett. 2017 Apr 5;22:8. doi: 10.1186/s11658-017-0038-0. eCollection 2017.
Squamous cell carcinoma (SCC) is the most common cancer worldwide. The treatment of locally advanced disease generally requires various combinations of radiotherapy, surgery, and systemic therapy. Despite aggressive multimodal treatment, most of the patients relapse. Identification of molecules that sustain cancer cell growth and survival has made molecular targeting a feasible therapeutic strategy. Survivin is a member of the Inhibitor of Apoptosis Protein (IAP) family, which is overexpressed in most of the malignancies including SCC and totally absent in most of the normal tissues. This feature makes survivin an ideal target for cancer therapy. It orchestrates several important mechanisms to support cancer cell survival including inhibition of apoptosis and regulation of cell division. Overexpression of survivin in tumors is also associated with poor prognosis, aggressive tumor behavior, resistance to therapy, and high tumor recurrence. Various strategies have been developed to target survivin expression in cancer cells, and their effects on apoptosis induction and tumor growth attenuation have been demonstrated. In this review, we discuss recent advances in therapeutic potential of survivin in cancer treatment.
鳞状细胞癌（SCC）是全球最常见的癌症。局部晚期疾病的治疗通常需要放疗、手术和全身治疗的各种组合。尽管进行了积极的多模式治疗，但大多数患者仍会复发。鉴定维持癌细胞生长和存活的分子使得分子靶向成为一种可行的治疗策略。生存素是凋亡抑制蛋白（IAP）家族的成员，在包括SCC在内的大多数恶性肿瘤中过度表达，而在大多数正常组织中完全不存在。这一特性使生存素成为癌症治疗的理想靶点。它协调多种重要机制以支持癌细胞存活，包括抑制凋亡和调节细胞分裂。肿瘤中生存素的过度表达还与预后不良、肿瘤侵袭性、治疗耐药性和高肿瘤复发率相关。已经开发了多种策略来靶向癌细胞中的生存素表达，并且已经证明了它们对诱导凋亡和减弱肿瘤生长的作用。在这篇综述中，我们讨论了生存素在癌症治疗中的治疗潜力的最新进展。
